54.35
Schlusskurs vom Vortag:
$54.72
Offen:
$54.61
24-Stunden-Volumen:
53,717
Relative Volume:
0.55
Marktkapitalisierung:
$229.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.82%
1M Leistung:
-0.98%
6M Leistung:
+11.76%
1J Leistung:
+40.95%
State Street Spdr S P Pharmaceuticals Etf Stock (XPH) Company Profile
Firmenname
State Street Spdr S P Pharmaceuticals Etf
Sektor
Branche
Telefon
-
Adresse
-
Compare XPH vs VTI, SPY, IVV, VB, QQQ
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
XPH
State Street Spdr S P Pharmaceuticals Etf
|
54.35 | 229.97M | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
325.21 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
658.93 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
661.86 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
265.51 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
588.50 | 124.43B | 0 | 0 | 0 | 0.00 |
State Street Spdr S P Pharmaceuticals Etf Aktie (XPH) Neueste Nachrichten
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a strong ETF right now? - MSN
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It. - 24/7 Wall St.
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now? - Yahoo Finance Singapore
No deal yet? Trump readies new tariffs on select drugmakersreport (SPY:NYSEARCA) - Seeking Alpha
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs - Barron's
Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead - 24/7 Wall St.
Is State Street SPDR S&P Aerospace & Defense ETF (XAR) a Strong ETF Right Now? - Yahoo Finance
Should you invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? - MSN
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? - Yahoo Finance
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance - 24/7 Wall St.
The 1-Minute Market Report, March 29, 2026 (NYSEARCA:SPY) - Seeking Alpha
KRE: Valuations Are Declining, But May Not Correct Soon (NYSEARCA:KRE) - Seeking Alpha
EU officials say Iran war raising risk of stagflation (SPY:NYSEARCA) - Seeking Alpha
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investor Concerns Linger Amid Middle East Conflict - Moomoo
Chart Of The Day: What Will Oil Stocks Do If Oil Goes Vertical? - Seeking Alpha
XMHQ Struggles To Earn Market-Beating Returns, Consider Alternatives (NYSEARCA:XMHQ) - Seeking Alpha
Stock List: Research Stocks from Around the World - GuruFocus
Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment - The Daily Upside
ValuEngine Weekly Market Summary And Commentary - Seeking Alpha
IAK: Understanding The Structure And Suitability Of This Insurance ETF (NYSEARCA:IAK) - Seeking Alpha
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0610 - MSN
Wall Street Lunch: Markets Seesaw After Trump’s Iran Pivot (undefined:SPY) - Seeking Alpha
Top performing semiconductor ETFs YTD, as sector rises on signals of war de-escalation (SMH:NASDAQ) - Seeking Alpha
Citi's large-cap stocks with negative ROE trends - Seeking Alpha
SA Asks: What can Congress do to protect Social Security benefits? - Seeking Alpha
SA Asks: What happens if the Social Security fund runs dry? - Seeking Alpha
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip - Benzinga
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip - Benzinga
Should State Street SPDR S&P 500 ETF Trust (SPY) Be on Your Investing Radar? - Yahoo Finance
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave - TradingView
Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes - Benzinga
These 5 Undervalued ETFs Could Be Bargains Right Now - AOL.com
South Korea's $350B U.S. Investment Pledge: ETFs That Could Gain - TradingView
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Should You Invest in the State Street SPDR S&P Retail ETF (XRT)? - Yahoo Finance
Is State Street SPDR S&P Oil & Gas Exploration & Production ETF (XOP) a Strong ETF Right Now? - Yahoo Finance
Better S&P 500 ETF: State Street's SPY vs. Vanguard's VOO - The Motley Fool
Most and least shorted healthcare stocks with up to $2B market cap in February - Seeking Alpha
Best S&P 500 ETFs to Buy in 2026 - The Motley Fool
How to Invest in SPDR S&P Biotech ETF (XBI) - The Motley Fool
Stock Market Today: Dow Jones, S&P500, Nasdaq Futures Decline After SC Strikes Down Trump's Emergency Tariffs— NVO, MSTR, VNDA In Focus (UPDATED) - Benzinga
XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning - AOL.com
State Street SPDR S&P Global Dividend ETF Holdings - Quiver Quantitative
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Yahoo Finance
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development - Stocktwits
PTC Therapeutics Faces Translarna Setback While Valuation Signals Potential Upside - simplywall.st
A Golden Age of Biotech Is Upon Us, Thanks to AI. This ETF Offers 40% Upside. - Barron's
Why Vertex Pharmaceuticals (VRTX) Is Up 6.0% After Profit Rebound And Non-CF Pipeline UpdateAnd What's Next - simplywall.st
NATCO Pharma Limited Just Missed Revenue By 8.4%: Here's What Analysts Think Will Happen Next - simplywall.st
Finanzdaten der State Street Spdr S P Pharmaceuticals Etf-Aktie (XPH)
Es liegen keine Finanzdaten für State Street Spdr S P Pharmaceuticals Etf (XPH) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):